Condition: B-cell Non-Hodgkin Lymphoma · Follicular Lymphoma (FL) · Large B-Cell Lymphoma (LBCL) · Sponsor: AstraZeneca
This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for LBCL.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Phoenix, Arizona, United States | Withdrawn |
| Research Site | Duarte, California, United States | Recruiting |
| Research Site | Jacksonville, Florida, United States | Withdrawn |
| Research Site | Tampa, Florida, United States | Recruiting |
| Research Site | Chicago, Illinois, United States | Recruiting |
| Research Site | Iowa City, Iowa, United States | Not Yet Recruiting |
| Research Site | Waukee, Iowa, United States | Recruiting |
| Research Site | Overland Park, Kansas, United States | Withdrawn |
| Research Site | Rochester, Minnesota, United States | Recruiting |
| Research Site | St Louis, Missouri, United States | Withdrawn |
| Research Site | New Brunswick, New Jersey, United States | Withdrawn |
| Research Site | New York, New York, United States | Recruiting |
+ 82 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06526793